This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example content
The efficacy and tolerability of Zinforo monotherapy has been consistently demonstrated in six large, double-blind, Phase III, randomised, controlled clinical trials: three involving adult patients with cSSTI and three in patients with CAP.2-5
System organ class |
Very common |
Common |
---|---|---|
Immune system disorders |
Rash, pruritus |
|
Nervous system disorders |
Headache, dizziness |
|
Vascular disorders |
Phlebitis |
|
Gastrointestinal disorders |
Diarrhoea†, abdominal pain, nausea, vomiting |
|
Hepatobiliary disorders |
Increased transaminases |
|
General disorders and administration site conditions |
Pyrexia, infusion site reactions (erythema, phlebitis, pain) |
|
Investigations |
Coombs Direct Test Positive |
Explore More
Abbreviations
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CE, clinically evaluable; CANVAS, Ceftaroline fosamil vs Vancomycin in Skin and skin structure infection; CI, confidence interval; MITT, modified intent-to-treat; PORT, Pneumonia Patient Outcomes Research Team; MRSA, Methicillin-resistant Staphylococcus aureus.
Prescribing Information
Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion
Footnotes
*Zinforo is contraindicated in patients with hypersensitivity to any active substance or excipient and should not be used in patients with a history of hypersensitivity to other cephalosporin-class antibiotics or who have had an immediate and severe hypersensitivity reaction (e.g., anaphylaxis to other β-lactam antibacterial agents). Fatal hypersensitivity reactions are possible.1 Antibacterial-associated colitis and pseudomembranous colitis (Clostridium difficile) have been reported including cases that were life-threatening.1Patients with a pre-existing seizure disorder should use Zinforo with caution as seizures occurred in toxicology studies at doses higher than typical human exposures.1 DAGT (Coombs test) became positive in 11.2% of patients from five pooled pivotal studies in patients who received Zinforo every 12 hours and in 32.3% of patients who received Zinforo every 8 hours. Although no patients developed haemolytic anaemia, there remains a potential risk.1 The most common adverse reactions occurring in ≥3% of patients treated with Zinforo were diarrhoea, headache, nausea, and pruritus and were generally mild or moderate in severity.1
ǁComparator therapies: cSSTI, ceftriaxone; CAP, vancomycin or cefazolin, plus optional aztreonam.
†Antibacterial-associated colitis and pseudomembranous colitis have been reported with ceftaroline fosamil and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of ceftaroline fosamil. In such circumstance, the discontinuation of therapy with ceftaroline fosamil and the use of supportive measures together with the administration of specific treatment for Clostridium difficile should be considered.
‡No clinical drug–drug interaction studies have been conducted with Zinforo.1
§The dose should be adjusted when CrCL is ≤50 mL/min.1
Abbreviations
cSSTI, complicated skin and soft tissue infection; CAP, community-acquired pneumonia.
Prescribing Information
Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion
References
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021